Brokerages expect that Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS) will announce earnings per share (EPS) of ($0.27) for the current quarter, according to Zacks. Five analysts have made estimates for Adamas Pharmaceuticals’ earnings, with estimates ranging from ($0.35) to ($0.20). Adamas Pharmaceuticals reported earnings of ($0.37) per share in the same quarter last year, which indicates a positive year over year growth rate of 27%. The firm is scheduled to report its next quarterly earnings report on Thursday, August 5th.
According to Zacks, analysts expect that Adamas Pharmaceuticals will report full year earnings of ($1.05) per share for the current year, with EPS estimates ranging from ($1.41) to ($0.74). For the next fiscal year, analysts expect that the company will post earnings of ($0.36) per share, with EPS estimates ranging from ($0.85) to $0.17. Zacks’ earnings per share calculations are a mean average based on a survey of sell-side research firms that that provide coverage for Adamas Pharmaceuticals.
Adamas Pharmaceuticals (NASDAQ:ADMS) last announced its quarterly earnings data on Sunday, May 9th. The specialty pharmaceutical company reported ($0.36) EPS for the quarter, beating the consensus estimate of ($0.51) by $0.15. The business had revenue of $19.31 million for the quarter, compared to analyst estimates of $19.59 million.
In related news, insider Vijay Shreedhar sold 6,200 shares of the business’s stock in a transaction on Monday, June 21st. The shares were sold at an average price of $5.16, for a total value of $31,992.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Insiders own 18.90% of the company’s stock.
A number of hedge funds and other institutional investors have recently modified their holdings of ADMS. The PNC Financial Services Group Inc. increased its holdings in Adamas Pharmaceuticals by 42.9% in the 1st quarter. The PNC Financial Services Group Inc. now owns 10,000 shares of the specialty pharmaceutical company’s stock worth $48,000 after acquiring an additional 3,000 shares in the last quarter. Walleye Capital LLC purchased a new stake in Adamas Pharmaceuticals in the 1st quarter worth $80,000. GSA Capital Partners LLP purchased a new stake in shares of Adamas Pharmaceuticals during the first quarter worth $101,000. Zebra Capital Management LLC purchased a new stake in shares of Adamas Pharmaceuticals during the first quarter worth $112,000. Finally, Grantham Mayo Van Otterloo & Co. LLC purchased a new stake in shares of Adamas Pharmaceuticals during the first quarter worth $189,000. 69.82% of the stock is owned by institutional investors.
NASDAQ ADMS traded up $0.17 on Friday, hitting $5.29. 653 shares of the company’s stock traded hands, compared to its average volume of 233,464. The company has a current ratio of 5.42, a quick ratio of 5.16 and a debt-to-equity ratio of 21.25. Adamas Pharmaceuticals has a 1-year low of $2.43 and a 1-year high of $9.15. The stock’s 50-day moving average price is $5.18.
Adamas Pharmaceuticals Company Profile
Adamas Pharmaceuticals, Inc focuses on the discovery, development, and commercialization of medicines for patients suffering from chronic neurologic disorders in the United States. It offers GOCOVRI, an extended release capsule for the treatment of dyskinesia in patients with Parkinson's disease receiving levodopa-based therapy, with or without concomitant dopaminergic medications, as well as an adjunctive treatment to levodopa/carbidopa in patients with Parkinson's disease experiencing OFF episodes; and OSMOLEX ER, an extended release tablet to treat Parkinson's disease and drug-induced extrapyramidal reactions in adult patients.
Further Reading: What Does An Overweight Rating Mean?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Adamas Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adamas Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.